ESR1 and breast carcinoma: To evaluate whether a second form of ADT was also capable of increasing the sensitivity of breast cancer cells to T cell lysis, 10 μM abiraterone or vehicle (DMSO) was used to treat ZR75-1 (ER+AR+) and MDA MB 231 (ER-AR-) cells.